Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postauthorization Safety Study of Repeat Darvadstrocel in Crohn’s Disease Perianal Fistula
2022-503014-23-00Phase 4Completed
- Sponsor
- Takeda
- Start
- Dec 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of darvadstrocel in Crohn's disease, sponsored by Takeda. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent serious adverse events and 2 more. Started Dec 2023; status: completed.
02
Drugs
darvadstrocel
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-503014-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503014-23-00.